跳至主要内容
临床试验/CTRI/2012/11/003104
CTRI/2012/11/003104招募中3 期

Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 per cycle for 3 cycles each as consolidation in AML ;an open label randomized non-inferiority study - AML-HIDAC 12/18 study

All India Institute of Medical Sciences0 个研究点目标入组 180 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • there shall be no upper age limit, if performance status permits patients of any age can be enrolled
  • -Confirmation of Acute Myeloid Leukemia by morphologic, immunophenotypic analysis
  • -Suitable for HIDAC as consolidation

排除标准

  • -Previous AML chemotherapy
  • [Hydroxyurea - not an exclusion.]
  • -Concurrent active malignancy
  • -HIV infection, Uncontrolled Hepatitis B/C
  • -Patients being considered for upfront PBSCT (before completion of CONSOLIDATION)
  • -Serum Bilirubin > 2
  • -Delayed recovery of blood counts /persistent active infection > 45 days from start of induction
  • -Patients receiving reinduction with HIDAC

研究者

相似试验